CER Daily Newsfeed

Video: Academic–Community Partnerships and Real-World Data in Value-Based Oncology: Jason Bergsbaken, PharmD, MBA, BCOP

(8/12, Jason Bergsbaken, PharmD, MBA, BCOP, Alana Hippensteele, MA, The American Journal of Managed Care) “Jason Bergsbaken, PharmD, MBA, BCOP, highlights the growing role of real-world data in validating or de-implementing therapies, the need for vigilant postapproval outcomes monitoring, and the value of academic–community oncology partnerships.” View Video

Drug Price Negotiations Pose Ruinous, Unconstitutional Dangers

(8/12, Daniel Troy, Bloomberg Law) comments “...These negotiations should be recognized as a sham. Pharmaceutical innovators are forced, under threat of financial penalties as high as 1,900% of daily revenue from all sources, to sell their patented medicines at government-dictated prices. This isn't bargaining-it's a coercive regime of price control masquerading as negotiation.” Subscription Required

Why Chiesi’s Raxone Faced a Decade-Long Wait For English Funding

(8/12, Eliza Slawther, Pink Sheet) reports “...Chiesi’s orphan drug Raxone has secured an English funding recommendation for the treatment of Leber's hereditary optic neuropathy, a decade after the orphan drug was approved for marketing. Chiesi told the Pink Sheet about its ‘long, and often challenging’ road to reimbursement.” Subscription Required